ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancersWith an FDA approval for HER2-positive breast cancer already in the bag, Daiichi Sankyo and AstraZeneca’s Enhertu now Share XASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancershttps://pharmaphorum.com/news/asco-2020-astrazeneca-enhertu-cancer/
Competition heats up in BCMA CAR-T as J&J, BMS update myeloma trialsBristol-Myers Squibb’s anti-BCMA CAR-T therapy ide-cel is in pole position to reach the market, but could face tough Share XCompetition heats up in BCMA CAR-T as J&J, BMS update myeloma trialshttps://pharmaphorum.com/news/bcma-jnj-bms-myeloma-trials/
Given after surgery, AZ’s Tagrisso prevents lung cancer coming backAstraZeneca opened its account at this year’ virtual ASCO meeting with data showing that adjuvant (post-surgery) use of Share XGiven after surgery, AZ’s Tagrisso prevents lung cancer coming backhttps://pharmaphorum.com/news/given-after-surgery-azs-tagrisso-prevents-lung-cancer-coming-back/
Atriva takes MEK inhibitor into phase 2 for COVID-19Atriva Therapeutics is starting a phase 2 trial of its MEK inhibitor ATR-002 in patients with coronavirus infections, Share XAtriva takes MEK inhibitor into phase 2 for COVID-19https://pharmaphorum.com/news/atriva-takes-mek-inhibitor-into-phase-2-for-covid-19/
PureTech to develop drug to treat lung scarring in COVID-19 patientsUS biotech PureTech is to develop its most advanced pipeline drug LYT-100 as a potential treatment for inflammation and Share XPureTech to develop drug to treat lung scarring in COVID-19 patientshttps://pharmaphorum.com/news/puretech-to-develop-drug-to-treat-lung-scarring-in-covid-19-patients/
Novartis builds case for MS drug ofatumumab as FDA decision loomsNovartis has reported new data with its multiple sclerosis (MS) drug ofatumumab showing that it can suppress disease Share XNovartis builds case for MS drug ofatumumab as FDA decision loomshttps://pharmaphorum.com/news/novartis-builds-case-for-ms-drug-ofatumumab-as-fda-decision-looms/
AI drug discovery firm Exscientia gets $60M cash injectionUK artificial intelligence specialist Exscientia has topped up its coffers with a $60 million Series C funding round Share XAI drug discovery firm Exscientia gets $60M cash injectionhttps://pharmaphorum.com/news/ai-drug-discovery-firm-exscientia-gets-60m-cash-injection/
Merck & Co and IAVI join forces to develop COVID-19 vaccineMerck & Co has joined with the non-profit scientific research organisation, the International AIDS Vaccine Initiative (IAVI), to Share XMerck & Co and IAVI join forces to develop COVID-19 vaccinehttps://pharmaphorum.com/news/merck-co-and-iavi-join-forces-to-develop-covid-19-vaccine/
WHO halts hydroxychloroquine trial in COVID-19 following safety concernsThe World Health Organisation has halted clinical tests of hydroxychloroquine against COVID-19, after safety concerns emerged in a Share XWHO halts hydroxychloroquine trial in COVID-19 following safety concernshttps://pharmaphorum.com/news/who-halts-hydroxychloroquine-trial-in-covid-19-following-safety-concerns/
